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AbsTrACT
Several clinical studies have shown a large number of 
mental symptoms by immunomodulatory treatment with 
interferon (IFN). The most frequently described symptoms 
are depression, suicidal behaviour, manic symptoms, 
anxiety, psychosis and delirium, associated with other 
non-specific symptoms such as fatigue, irritability, 
psychomotor retardation, decreased libido, insomnia, 
difficulty in concentration and attention. Having a history 
of mental disorder contraindicates the use of IFN-alpha. 
These adverse effects that affect the mental state appear 
usually at the beginning of the treatment (most after 3 
weeks of treatment). The incidence of psychotic episodes 
is low and the episodes usually remit when treatment 
is interrupted; only some cases require antipsychotic 
treatment. We present the case of a patient affected with 
hepatitis C who began to present self-referential delirious 
symptoms after receiving the treatment with IFN and who 
was successfully treated with paliperidone. This patient 
could be classified within the group of high-risk psychiatric 
patients given the family history of schizophrenia and 
his personal history of illegal drug consumption. The 
pharmacological actions of paliperidone are similar to 
other high potency atypical antipsychotics. The receptor-
binding profile of paliperidone most closely resembles that 
of risperidone and ziprasidone. Paliperidone differs from 
risperidone and most other antipsychotics by its relatively 
low extent of enzymatic hepatic metabolism. To the best 
of our knowledge, this is the first case described that was 
successfully treated with paliperidone.
InTroduCTIon
Addictions and mental illness comorbidity 
are more frequent in patients with chronic 
hepatitis C than in the general population. In 
addition, the treatment with interferon alpha 
(IFN-α) frequently results in psychiatric side 
effects, which are the risk factors for a failed 
treatment, leading to a major impact on the 
quality of life and reduction of therapeutic 
adherence.1 2
Pegylated antiviral therapies and high-stan-
dard IFN in combination with ribavirin are 
frequently associated with psychiatric side 
effects, which can occur in 30%–80% of 
patients under treatment.3
Moderate depressive syndromes can appear 
in up to 70% of the cases and major depres-
sive episodes around 15%–45%. Fatigue is 
the most prominent side effect, occurring 
in 80% of cases. Anger, irritability and/
or hostility have been described in 50% of 
treated patients.2 Alterations in sleep, anxiety, 
cognitive alterations can occur in 50% of 
cases. In contrast, mania and psychosis are 
very infrequent side effects, which can reach 
up to 3%. Finally, suicidal thoughts have been 
described in 10% of patients under treatment 
with IFN-α, with some cases of completed 
suicide.4
Specifically, ribavirin is known to cause 
haemolytic anaemia, while boceprevir is asso-
ciated with irritability, insomnia, anaemia and 
dysgeusia.5
There are some other risk factors which 
need to be contemplated such as previous 
history of affective disorder, sleep distur-
bances, advanced age, organic brain 
alteration (vascular pathology, AIDS enceph-
alopathy, etc), together with limited social 
and functional support.4
Paliperidone, which is pharmacologically 
identical to 9-hydroxyrisperidone, exhibits 
high affinities for dopamine type 2 and sero-
tonin 5-hydroxytryptamine-2 receptors but 
does not undergo significant hepatic metab-
olism. The drug is well tolerated in patients 
with poor hepatic function and seems 
unlikely to be susceptible to metabolic drug 
interactions.6
CAse reporT
A 34-year-old man was referred to the mental 
health unit by the digestive system specialist. 
The patient presented psychotic symptoms 
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after the treatment for hepatitis C virus (HCV) infection 
with pegylated IFN-α-2b 3 MU, subcutaneously, 3 days a 
week and ribavirin in 200 mg oral tablets at a dose of 1000 
mg/day for 3 weeks.
personal history
 ► Medical–surgical antecedents: chronic hepatopathy 
in cirrogenic evolution by HCV (genotype Ia).
 ► Illegal drugs: former illicit drug addict parenterally 
(heroin); former consumer of cocaine and cannabis. 
Follow-up by an illegal drug addiction centre since the 
age of 30.
 ► Psychiatric antecedents: self-limited cocaine induced 
psychosis, which did not require treatment.
Family background
The patient’s father had been diagnosed with non-spec-
ified psychosis, and his grandfather was diagnosed with 
schizophrenia.
Current illness
After the first 3 weeks of the administration of antiretro-
viral treatment, the patient began to present behavioural 
changes and sleep–wake inversion coexisting with 
decreased sleep needs. He exhibited delusions of persecu-
tion and filiation (asserting that he was not the biological 
son of his mother). He also showed an unstructured reli-
gious mystical ideation (he believed that he was involved 
in some divine plans).
He presented intrusive and ego-dystonic obsessive ideas, 
which he recognised as not very rational and contained 
sexual contents towards his grandmother, but these were 
not accompanied by compulsive behaviours. These ideas 
generated great anguish. He exhibited hallucinations in 
the form of voices that he recognised as his father and a 
psychologist who attended him years ago. He presented 
soliloquies (he had conversations about his work, his life 
with these people). For this reason, antiretroviral treat-
ment was withdrawn, despite not having complied with 
the 48 weeks recommended duration. Undetectable viral 
load was not accomplished either. He was immediately 
referred to the mental health unit.
physical examination
 ► Cardiopulmonary auscultation: within normality.
 ► Abdominal examination: hepatomegaly as the only 
remarkable finding
psychopathological exploration
He was presented as a middle-aged man, with a careful 
and suitable behavioural appearance. He was conscious 
and oriented, and he was approachable and collaborative.
There was a slight decrease in attention and 
concentration.
Immediate memory did not present alterations. There 
was an increase in speech pressure. He exhibited delu-
sional ideation of prejudice, filiation and poorly struc-
tured religious mystic themes. The mood was hyperthymic, 
with restlessness and without respecting the interpersonal 
distance, and slightly uninhibited. He exhibited auditory 
hallucinations in the second and third person and he 
displayed echo and thought phenomena. The patient 
verbalised obsessive ideas and delusional ideation of 
non-systematised persecution. There was no desire for 
death or tanatic ideation. He presented global insomnia 
and hyporexia. Null disease awareness at the moment.
supplementary tests
 ► Haemogram: haematies 4 950 000 mm3; haemoglobin 
16.5 g/L; haematocrit 48.4%; mean corpuscular 
velocity 97.7 fL; mean corpuscular haemoglobin 33.4 
pg; platelets 134x 109g/L; rest within normality.
 ► Biochemistry: aspartate transaminase 114 U/L; 
alanine aminotransferase 177 U/L; gamma-glutamyl 
transpeptidase 188 U/L.
 ► Thyroid stimulating hormone: 3.2 mIU/L; alfafeto-
protein 2 µg/L.
 ► Coagulation, lipid profile, vitamin B12 and folic acid: 
within normality.
 ► Serologies: syphilis, Borrelia, HIV, Epstein-Barr virus, 
cytomegalovirus and hepatitis B virus negative; posi-
tive HCV.
 ► Abdominal ultrasound: liver with a rough appearance, 
with somewhat irregular borders and left hepatic lobe 
enlarged, without space-occupying lesions; normal 
hepatopetal flow portal; rest without significant find-
ings. The findings are suggestive of chronic hepatop-
athy in cirrogenic evolution.
diagnosis
In our case, we detected delusional ideation of harm, 
filiation and religious mysticism, as well as hallucinations 
in the second and third person. The conscience was not 
affected.
He was diagnosed as IFN-induced and rivabirin-in-
duced psychosis following the criteria for the suspected 
diagnosis of psychosis by IFN-α:
 ► Start of symptoms before 3 weeks of treatment.
 ► Family history of mental disorder.
 ► Personal history of psychosis, affective disorder, altera-
tions in sleep, advanced age, organic brain alteration, 
toxic consumption.
 ► Key symptoms such as delusional ideation, thought 
disorders, hallucinations or affective alterations.
evolution and treatment
The progressive increase of transaminases in the last 6 
months required the choice of an antipsychotic avoiding 
hepatic metabolisation. Paliperidone extended release 
(ER) is an atypical antipsychotic that, unlike other anti-
psychotics, is not extensively metabolised in the liver.7 
A pharmacokinetic analysis in patients with moderate 
hepatic impairment and healthy volunteers showed that 
unbound plasma concentrations of paliperidone ER were 
similar between the populations.8 Consequently, no dose 
adjustment is required in patients with mild or moderate 
hepatic impairment.9
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Different studies suggest that paliperidone is well 
tolerated in patients with schizophrenia or schizoaffec-
tive disorder who have a stable active hepatic disease.10 
Initially, he was treated with oral paliperidone in a dose of 
6 mg/24 hours and it was switched to intramuscular pali-
peridone palmitate after 14 days due to the patient’s very 
poor oral medication adherence and good response to 
oral paliperidone. The psychotic symptomatology dimin-
ished until it was encapsulated. Previous treatment with 
methadone at 40 mg was maintained.
The auditory hallucinations were translated in the 
chronic form but with very poor affective repercussion, 
except in moments of a lot of hallucinatory activities, in 
which the patient tended to isolate himself and he only 
responded to the auditory hallucinations that provoked 
him. These episodes lasted about 2 weeks and were 
resolved by temporarily increasing of the antipsychotic. 
The intercrisis periods lasted several months. The aware-
ness of the disease had been increasing until the patient 
adequately criticised the psychotic symptoms, but the 
biographical rupture persisted after receiving antiretro-
viral treatment.
In the last 2 years, the progression of hepatopathy had 
produced asthenia and problems in the digestive sphere 
in the patient. He had a feeling of disability and inca-
pacity with reactive hypotonia in this vital situation.
Currently, a treatment with paliperidone at a dose of 3 
mg/day and methadone ratio of 40 mg/day is ongoing.
The hallucinatory activity is chronic, although with 
little emotional repercussion, it is prescribed in the low 
doses (3 mg) of maintenance for the control of the 
symptomatology.
dIsCussIon
Approximately 13% of patients with HCV receiving 
treatment with IFN-α have neuropsychiatric symp-
toms such as depression, anxiety, suicidal ideation or 
psychosis; the latter is observed in 1% of the cases.1 
Among the most frequent psychotic symptoms are the 
presence of auditory hallucinations and delusions of 
persecution. These symptoms have been recognised as 
a valid reason to interrupt the treatment, but there are 
cases in which the symptoms do not stop after removing 
it, despite receiving antipsychotics, as is the case with 
our patient.2 3
There are several proposed biological mechanisms 
underlying this proinflammatory-induced neurodegen-
erative effect including upregulation of the central sero-
tonin transporter molecular, a decrease in neurogenesis 
in brain-neuronal circuits regulating mood, changes 
in tryptophan metabolism via activation of the enzyme 
indoleamine-D-oxygenase, changes in central glutamate 
metabolism, activation of the hypothalamic–pituitary–
adrenal axis and alteration in cellular apoptosis mecha-
nisms. How these mechanisms may interact is not clearly 
understood.11
In addition to the genetic and environmental risk 
factors for psychosis that our patient presents, has been 
able to favour the appearance of this disorder.
Regarding prevention, it would be a contribution to 
include the high psychiatric risk as a special group and 
study subjects. These high-risk groups must have psycho-
logical and psychiatric support at different times of treat-
ment. Future studies should demonstrate efficient and 
effective models for research and longitudinal monitoring 
during the course of treatment, to standardise interven-
tion and treatment models, in addition to focusing on 
extending management including depressive syndrome, 
evaluating anxious disorders, management of anger 
and mania and designing a multidisciplinary strategy to 
reduce the deterioration of the quality of life of these 
patients.
This is a clear example of how we underestimated 
correct anamnesis before selecting the treatment.
So far, this is the first published case found in a 
review through the PubMed search engine of psychosis 
secondary to treatment with IFN, and successfully treated 
with paliperidone.
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